NeoCura

Focus: NeoCura is a China-based biotechnology company specializing in personalized neoantigen tumor vaccines for solid tumors and gastrointestinal cancers. The company operates in the high-growth personalized oncology vaccine space with a focused pipeline.

Infectious Diseases Vaccines

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About NeoCura

AI assessmentNot Hiring

No open roles listed right now. Follow NeoCura to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

7 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

XH001

Pancreatic Cancer

N/A

Clinical Trials (1)

NCT06353646XH001 Combination With Immunocheckpoint Inhibitor and Chemotherapy for Patients With Resected Pancreatic Cancer

N/A

Help build intelligence for NeoCura

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Early-stage exposure to cutting-edge personalized neoantigen vaccine technology in oncology, a rapidly growing therapeutic area
Opportunity to build from the ground up in a pre-revenue biotech focused on unmet needs in solid tumors and gastric cancer
China-based headquarters provides access to large patient populations and emerging biotech ecosystem

Watch Out For

No active job openings currently listed, indicating minimal near-term hiring or potential organizational challenges
Pre-revenue stage with limited public financial data creates uncertainty around company stability and funding runway
Early-stage pipeline (majority programs in Phase 1 or undisclosed phase) means long timeline to clinical validation and commercial potential

Generated by Claude from NeoCura's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

neoantigen tumor vaccine with or without PD-1/L1

Gastric Cancer

N/A

Clinical Trials (1)

NCT05192460Safety and Efficacy of Personalized Neoantigen Vaccine in Advanced Gastric Cancer, Esophageal Cancer and Liver Cancer

N/A

neoantigen tumor vaccine with or without PD-1/L1

Gastric Cancer

N/A

Clinical Trials (1)

NCT05227378Safety and Efficacy of Personalized Neoantigen Vaccine in Advanced Gastric Cancer

N/A

Personalized neoantigen tumor vaccine

Solid Tumor

N/A

Clinical Trials (1)

NCT05359354Safety and Efficacy of Personalized Neoantigen Vaccine in Advanced Solid Tumors

N/A

XH001+ sintilimab

Solid Tumor

N/A

Clinical Trials (1)

NCT05940181A Safety and Efficacy Study of XH001 Combined With Sintilimab Injection in Advanced Solid Tumors

N/A

XH001 Injection

Advanced Gastric Cancer

Phase 1

Clinical Trials (1)

NCT07298200Clinical Trial on the Safety, Tolerance and Preliminary Efficacy of XH001 Injection Combined With Neoantigen Vaccine-induced Tumor-specific T-cell Injection in Advanced Gastric Cancer

Phase 1

XH001 injection

Gastrointestinal Cancer

Phase 1

Clinical Trials (1)

NCT07329894Safety, Tolerance and Preliminary Efficacy of XH001 Injection Combined With Neoantigen Vaccine-induced Tumor-specific T-cell Injection in Advanced Gastrointestinal Cancer

Phase 1

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 7 clinical trials

Top TAs: Oncology

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Oncology

7 pipeline

Marketed

Pipeline